ClinicalTrials.gg
Active, not recruitingNCT06035497Updated Oct 7, 2026

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

A Phase 1/2 interventional study of BMS-986369 in Relapsed or Refractory T-cell Lymphomas, sponsored by Bristol-Myers Squibb. Active, not recruiting at 40 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Primary conditionLymphoma, T-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, T-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, T-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Updated Oct 7, 2026Primary completion movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).

02

Conditions studied

  • Relapsed or Refractory T-cell Lymphomas

Keywords

  • Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
  • Relapsed or Refractory Adult T-cell Leukemia/Lymphoma (R/R ATL)
  • Golcadomide
  • BMS-986369
  • CC-99282
  • Adult T-cell leukemia/lymphoma (ATL)
  • Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)
  • Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper (TFH) cell origin
  • Angioimmunoblastic T-cell lymphoma (AITL)
  • Follicular T-cell lymphoma (FTCL)
  • Nodal peripheral T-cell lymphoma with TFH phenotype
  • Anaplastic large cell lymphoma, ALK-positive (ALCL, ALK+)
  • Anaplastic large cell lymphoma, ALK-negative (ALCL, ALK-)
  • Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)
  • Extranodal NK/T-cell lymphoma, nasal type (ENKL)
  • Mycosis fungoides (MF)
03

In context

Lymphoma, T-Cell Reclassified

310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.

This study's planned enrollment of 83 is above the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.

Browse Lymphoma, T-Cell studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Lymphoma, T-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Have one of the following subtypes of T-cell Lymphoma (TCL) with disease, as assessed by the investigator:.

i) Adult T-cell leukemia-lymphoma (ATL).

ii) Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).

iii) Angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of T follicular helper phenotype (TFH) cell origin.

iv) Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase-positive (ALK+).

v) ALCL, anaplastic lymphoma kinase-negative (ALK-).

vi) Breast implant-associated ALCL.

vii) Extranodal NK/T-cell lymphoma, nasal type (ENKL).

viii) Mycosis fungoides (MF) with advanced stage (stage IIB-IVB).

  • Phase 1 participants must not be responsive, intolerant, or ineligible to standard therapies that may prolong life or provide symptomatic relief, or for whom no standard therapeutic option is available in the clinical practice guidelines in the opinion of the investigator.
  • Phase 2 participants must have been treated by at least 1 .
  • Have an performance status of 0, 1 or 2.

Exclusion criteria

Exclusion Criteria

  • Have any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participants from participating in the study.
  • Have any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, which places the participants at unacceptable risk if he/she were to participate in the study.
  • Have a ≤ 3 months.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (estimated)

Study arms

  • Experimental
    Administration of BMS-986369

    Drug: BMS-986369

Interventions

  • Specified dose on specified days

    Also known as: Golcadomide, CC-99282

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Phase 1 participants

    Time frame: Up to 5 weeks after last dose of treatment

  2. Number of participants with treatment-emergent adverse events (TEAEs)

    Phase 1 participants

    Time frame: Up to 5 weeks after last dose of treatment

  3. Number of participants with Dose-Limiting Toxicity (DLT)

    Phase 1 participants

    Time frame: Up to 28 days after first dose

  4. Number of participants with laboratory abnormalities

    Phase 1 participants

    Time frame: Up to 5 weeks after last dose of treatment

  5. Number of participants with vital sign abnormalities

    Phase 1 participants

    Time frame: Up to 5 weeks after last dose of treatment

  6. Number of participants with Electrocardiogram (ECG) abnormalities

    Phase 1 participants

    Time frame: Up to 5 weeks after last dose of treatment

  7. Eastern Cooperative Oncology Group Performance Status (ECOG PS)

    Phase 1 participants

    Time frame: Up to 5 weeks after last dose of treatment

  8. Number of participants with Left Ventricular Ejection Fraction (LVEF) assessment abnormalities

    Phase 1 participants

    Time frame: Up to 5 weeks after last dose of treatment

  9. Number of participants with Physical Examination (PE) abnormalities

    Phase 1 participants

    Time frame: Up to 5 weeks after last dose of treatment

  10. Number of participants who achieve Objective Response (OR) as assessed by central review per international consensus response criteria for ATL

    Phase 2: Adult T-cell Leukemia-Lymphoma (ATL) cohort OR is defined as the achievement of Partial Response (PR), complete response unconfirmed (CRu), or Complete Response (CR)

    Time frame: Up to 2 years after last does of treatment

  11. Number of participants who achieve OR as assessed by central review per protocol-defined response criteria according to Lugano classification (Computed Tomography(CT)-based)

    Phase 2: Peripheral T-cell Lymphoma (PTCL) cohort OR is defined as the achievement of PR or CR

    Time frame: Up to 2 years after last dose of treatment

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 8 of Cycle 2 (each cycle is 28 days)

  2. Area under the plasma concentration time-curve (AUC)

    Time frame: Up to Day 8 of Cycle 2 (each cycle is 28 days)

  3. Time to peak (maximum) plasma concentration (Tmax)

    Time frame: Up to Day 8 of Cycle 2 (each cycle is 28 days)

  4. Number of participants with AEs

    Phase 2 participants

    Time frame: Up to 5 weeks after last dose of treatment

  5. Number of participants with TEAEs

    Phase 2 participants

    Time frame: Up to 5 weeks after last dose of treatment

  6. Number of participants with laboratory abnormalities

    Phase 2 participants

    Time frame: Up to 5 weeks after last dose of treatment

  7. Number of participants with vital sign abnormalities

    Phase 2 participants

    Time frame: Up to 5 weeks after last dose of treatment

  8. Number of participants with ECG abnormalities

    Phase 2 participants

    Time frame: Up to 5 weeks after last dose of treatment

  9. ECOG PS

    Phase 2 participants

    Time frame: Up to 5 weeks after last dose of treatment

  10. Number of participants with LVEF assessment abnormalities

    Phase 2 participants

    Time frame: Up to 5 weeks after last dose of treatment

  11. Number of participants with PE abnormalities

    Phase 2 participants

    Time frame: Up to 5 weeks after last dose of treatment

  12. Number of participants who achieve OR as assessed by central review per international consensus response criteria for ATL

    ATL participants OR is defined as the achievement of PR, CRu, or CR

    Time frame: Up to 4 years after last dose of treatment

  13. Number of participants who achieve OR as assessed by investigator per international consensus response criteria for ATL

    ATL participants OR is defined as the achievement of PR, CRu, or CR

    Time frame: Up to 4 years after last dose of treatment

  14. Number of participants who achieve OR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based).

    PTCL participants OR is defined as the achievement of PR or CR

    Time frame: Up to 4 years after last dose of treatment

  15. Number of participants who achieve OR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based).

    PTCL participants OR is defined as the achievement of PR or CR

    Time frame: Up to 4 years after last dose of treatment

  16. Number of participants who achieve disease control as assessed by central review per international consensus response criteria for ATL

    ATL participants Disease control is considered to be stable disease (SD), PR, CRu, or CR

    Time frame: Up to 4 years after last dose of treatment

  17. Number of participants who achieve disease control as assessed by investigator per international consensus response criteria for ATL

    ATL participants Disease control is considered to be SD, PR, CRu, or CR

    Time frame: Up to 4 years after last dose of treatment

  18. Number of participants who achieve CR as assessed by central review per international consensus response criteria for ATL

    ATL participants

    Time frame: Up to 4 years after last dose of treatment

  19. Number of participants who achieve CR as assessed by investigator per international consensus response criteria for ATL

    ATL participants

    Time frame: Up to 4 years after last dose of treatment

  20. Time to response (TTR) as assessed by central review per international consensus response criteria for ATL

    ATL participants

    Time frame: Up to 4 years after last dose of treatment

  21. TTR as assessed by investigator per international consensus response criteria for ATL

    ATL participants

    Time frame: Up to 4 years after last dose of treatment

  22. Duration of response (DOR) as assessed by central review per international consensus response criteria for ATL

    ATL Participants

    Time frame: Up to 4 years after last dose of treatment

  23. DOR as assessed by investigator per international consensus response criteria for ATL

    ATL Participants

    Time frame: Up to 4 years after last dose of treatment

  24. Progression Free Survival (PFS) as assessed by central review per international consensus response criteria for ATL

    ATL participants

    Time frame: Up to 4 years after last dose of treatment

  25. PFS as assessed by investigator per international consensus response criteria for ATL

    ATL participants

    Time frame: Up to 4 years after last dose of treatment

  26. Number of participants who achieve disease control as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants Disease control is considered to be SD, PR or CR

    Time frame: Up to 4 years after last dose of treatment

  27. Number of participants who achieve disease control as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants Disease control is considered to be SD, PR or CR

    Time frame: Up to 4 years after last dose of treatment

  28. Number of participants who achieve CR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants

    Time frame: Up to 4 years after last dose of treatment

  29. Number of participants who achieve CR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants

    Time frame: Up to 4 years after last dose of treatment

  30. TTR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants

    Time frame: Up to 4 years after last dose of treatment

  31. TTR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants

    Time frame: Up to 4 years after last dose of treatment

  32. DOR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants

    Time frame: Up to 4 years after last dose of treatment

  33. DOR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants

    Time frame: Up to 4 years after last dose of treatment

  34. PFS as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants

    Time frame: Up to 4 years after last dose of treatment

  35. PFS as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)

    PTCL participants

    Time frame: Up to 4 years after last dose of treatment

  36. Time to next treatment (TTNT)

    Time frame: From the date of last dose until the date of death, lost to follow-up, withdrawal of consent from the entire study, time to next treatment or the end of the trial, whichever occurs first, assessed up to 2 years after end of treatment.

  37. Overall survival (OS)

    Time frame: From the date of last dose until the date of death, lost to follow-up, withdrawal of consent from the entire study, or the end of the trial, whichever occurs first, assessed up to 2 years after end of treatment.

07

Study locations

40 sites
  • Local Institution - 0031
    Anjo-shi, Aichi-ken 446-8602, Japan
  • Local Institution - 0011
    Nagoya, Aichi-ken 467-8602, Japan
  • Local Institution - 0024
    Toyohashi, Aichi-ken 441-8570, Japan
  • Local Institution - 0017
    Kamogawa, Chiba 296-0041, Japan
  • Local Institution - 0002
    Kashiwa, Chiba 277-8577, Japan
  • Local Institution - 0037
    Narita, Chiba 286-8520, Japan
  • Local Institution - 0016
    Iizuka, Fukuoka 820-8505, Japan
  • Local Institution - 0041
    Kitakyushu-shi, Fukuoka 806-8501, Japan
  • Local Institution - 0036
    Sapporo, Hokkaido 0608648, Japan
  • Local Institution - 0032
    Amagasaki, Hyōgo 660-8550, Japan
  • Local Institution - 0033
    Kobe, Hyōgo 650-0047, Japan
  • Local Institution - 0004
    Isehara, Kanagawa 259-1193, Japan
  • Local Institution - 0013
    Yokosuka, Kanagawa 238-8558, Japan
  • Local Institution - 0001
    Sendai, Miyagi 980-8574, Japan
  • Local Institution - 0019
    Ōmura, Nagasaki 8568562, Japan
  • Local Institution - 0028
    Sasebo, Nagasaki 857-8511, Japan
  • Local Institution - 0005
    Ōsaka-sayama, Osaka 589-8511, Japan
  • Local Institution - 0009
    Hidaka, Saitama 350-1298, Japan
  • Local Institution - 0003
    Chuo-ku, Tokyo 104-0045, Japan
  • Local Institution - 0029
    Itabashiku, Tokyo 173-8610, Japan
  • Local Institution - 0040
    Koto, Tokyo 135-8550, Japan
  • Local Institution - 0026
    Minato-ku, Tokyo 105-8471, Japan
  • Local Institution - 0018
    Fukuoka, 810-8563, Japan
  • Local Institution - 0012
    Fukuoka, 812-8582, Japan
  • Local Institution - 0023
    Fukuoka, 814-0180, Japan
  • Local Institution - 0039
    Hiroshima, 730-0052, Japan
  • Local Institution - 0025
    Hiroshima, 7348551, Japan
  • Local Institution - 0015
    Kagoshima, 890-0064, Japan
  • Local Institution - 0008
    Kagoshima, 890-8520, Japan
  • Local Institution - 0035
    Kumamoto, 860-0008, Japan
  • Local Institution - 0006
    Kumamoto, 860-8556, Japan
  • Local Institution - 0027
    Kyoto, 602-8566, Japan
  • Local Institution - 0022
    Mitaka, 181-8611, Japan
  • Local Institution - 0038
    Miyazaki, 889-1692, Japan
  • Local Institution - 0030
    Nagasaki, 852-8104, Japan
  • Local Institution - 0007
    Okayama, 700-8558, Japan
  • Local Institution - 0042
    Okinawa, 904-2142, Japan
  • Local Institution - 0010
    Osaka, 541-8567, Japan
  • Local Institution - 0034
    Osaka, 545-8586, Japan
  • Local Institution - 0020
    Ōita, 870-8511, Japan
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Aug 2026, 32 months.

Of 29 phase 1/2 interventional studies under Lymphoma, T-Cell, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 92. This study's 32 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Aug 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2023
First posted
Sep 13, 2023
StartActual
Nov 20, 2023
Primary completionActual
Aug 11, 2026was Jan 2027
CompletionEst.
Oct 10, 2030
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 30, 2027→Aug 11, 2026 (actual)
Oct 7, 2026
Enrollment
85→83
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion Jan 30, 2027→Aug 11, 2026 (now actual)
    Enrollment 85→83
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06035497
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Nov 20, 2023
Primary completion
Aug 11, 2026
Completion
Oct 10, 2030 (estimated)
Last update
Oct 7, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion